Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
13.52
+0.64 (4.97%)
At close: Sep 4, 2025, 4:00 PM
13.30
-0.22 (-1.63%)
After-hours: Sep 4, 2025, 4:24 PM EDT
Mesoblast Revenue
In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M with 191.39% growth. Mesoblast had revenue of $14.04M in the half year ending June 30, 2025, with 244.25% growth.
Revenue (ttm)
$17.20M
Revenue Growth
+191.39%
P/S Ratio
96.36
Revenue / Employee
$235,589
Employees
73
Market Cap
1.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
MESO News
- 22 hours ago - Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - GlobeNewsWire
- 6 days ago - Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil® - GlobeNewsWire
- 6 weeks ago - Successful Commercial Launch of Ryoncil® - GlobeNewsWire
- 2 months ago - Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Benzinga
- 2 months ago - Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure - GlobeNewsWire
- 3 months ago - Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD - GlobeNewsWire
- 4 months ago - FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil® - GlobeNewsWire